Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir

Gretja Schnell, Rakesh Tripathi, Preethi Krishnan, Jill Beyer, Thomas Reisch, Michelle Irvin, Tatyana Dekhtyar, Carolyn Setze, Lino Rodrigues Jr, Katia Alves, Margaret Burroughs, Rebecca Redman, Kazuaki Chayama, Hiromitsu Kumada, Christine Collins, Tami Pilot-Matias, Gretja Schnell, Rakesh Tripathi, Preethi Krishnan, Jill Beyer, Thomas Reisch, Michelle Irvin, Tatyana Dekhtyar, Carolyn Setze, Lino Rodrigues Jr, Katia Alves, Margaret Burroughs, Rebecca Redman, Kazuaki Chayama, Hiromitsu Kumada, Christine Collins, Tami Pilot-Matias

Abstract

Treatment of HCV genotype (GT) 2-infected Japanese patients with paritaprevir (NS3/4A inhibitor boosted with ritonavir) and ombitasvir (NS5A inhibitor) without ribavirin for 12 weeks in the phase 2 study M12-536, and with ribavirin for 16 weeks in phase 3 study GIFT II resulted in SVR rates of 72.2% to 91.5%. Overall, 11 out of 125 patients with GT2a and 37 out of 79 patients with GT2b infection experienced virologic failure. The prevalence of baseline polymorphisms in NS3 and NS5A and their the impact on treatment outcome, as well as the development of viral resistance in GT2-infected patients experiencing virologic failure were evaluated by HCV NS3 and NS5A population and clonal sequence analyses. Baseline polymorphisms in NS3 that confer resistance to paritaprevir were rare in both GT2a- and GT2b-infected patients, while baseline polymorphisms in NS5A that confer resistance to ombitasvir were detected in 11.2% and 14.1% of the GT2a- and GT2b-infected patients, respectively. There was no significant impact of baseline polymorphisms on treatment outcome in Japanese patients. The most common treatment-emergent substitutions at the time of virologic failure occurred at amino acid positions 168 in NS3 and 28 in NS5A in both GT2a- and GT2b-infected patients. Although there was a higher rate of virologic failure in patients with GT2b infection, the resistance analyses presented in this report support the conclusion that testing for baseline resistance-associated polymorphisms is not warranted for HCV GT2-infected patients treated with a regimen of ombitasvir/paritaprevir/ritonavir + ribavirin for 16 weeks.

Trial registration: ClinicalTrials.gov NCT01672983.

Keywords: genotype 2; hepatitis C virus; ombitasvir; paritaprevir.

© 2017 The Authors. Journal of Medical Virology Published by Wiley Periodicals, Inc.

Figures

Figure 1
Figure 1
Persistence of resistance‐associated baseline polymorphisms and treatment‐emergent substitutions in GT 2a or 2b‐infected patients who experienced virologic failure. The percentage of VF patients with the designated baseline or treatment‐emergent substitution is shown for the baseline, time of VF, post‐treatment week 24, and post‐treatment week 48 time points. Columns denoted as “Any” include patients with any baseline polymorphism or treatment‐emergent substitution for NS3 or NS5A at signature resistance‐associated amino acid positions. Baseline polymorphisms L/M31 in NS5A were not included in the total “Any” count. Specific amino acid substitutions designated as “(any)” include any amino acid change from wild‐type in the total count

References

    1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age‐specific antibody to HCV seroprevalence. Hepatology. 2013; 57:1333–1342.
    1. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014; 59:318–327.
    1. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015; 61:77–87.
    1. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology. 2010; 53:39–43.
    1. Toyoda H, Kumada T, Takaguchi K, Shimada N, Tanaka J. Changes in hepatitis C virus genotype distribution in Japan. Epidemiol Infect. 2014; 142:2624–2628.
    1. Ashtari S, Pourhoseingholi MA, Sharifian A, Zali MR. Hepatocellular carcinoma in Asia: prevention strategy and planning. World J Hepatol. 2015; 7:1708–1717.
    1. Chayama K, Notsumata K, Kurosaki M, et al. Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus‐infected patients. Hepatology. 2015; 61:1523–1532.
    1. Kumada H, Chayama K, Rodrigues L, Jr. , et al. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b‐infected Japanese patients with or without cirrhosis. Hepatology. 2015; 62:1037–1046.
    1. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014; 59:2083–2091.
    1. Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed‐dose combination with and without ribavirin for 12 weeks in treatment‐naive and previously treated Japanese patients with genotype 1 hepatitis C: an open‐label, randomised, phase 3 trial. Lancet Infect Dis. 2015; 15:645–653.
    1. Bourliere M, Benali S, Ansaldi C, Le Folgoc G, Riso A, Lecomte L. Optimal therapy of genotype‐2 chronic hepatitis C: what's new? Liver Int. 2015; 35:21–26.
    1. Marcellin P, Cheinquer H, Curescu M, et al. High sustained virologic response rates in rapid virologic response patients in the large real‐world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology. 2012; 56:2039–2050.
    1. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa‐2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007; 357:124–134.
    1. Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open‐label, phase 3 trial. J Viral Hepat. 2014; 21:762–768.
    1. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014; 370:1993–2001.
    1. Chayama K, Hayes CN. HCV drug resistance challenges in Japan: the role of pre‐existing variants and emerging resistant strains in direct acting antiviral therapy. Viruses. 2015; 7:5328–5342.
    1. DeGoey DA, Randolph JT, Liu D, et al. Discovery of ABT‐267, a pan‐genotypic inhibitor of HCV NS5A. J Med Chem. 2014; 57:2047–2057.
    1. Menon RM, Klein CE, Lawal AA, et al. Pharmacokinetics and tolerability of the HCV protease inhibitor ABT‐450 following single ascending doses in healthy adult volunteers with and without ritonavir. Global Antiviral J. 2009; 5:53.
    1. Krishnan P, Beyer J, Mistry N, et al. In vitro and In vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother. 2015; 59:979–987.
    1. Sato K, Chayama K, Alves K, et al. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir and ribavirin for hepatitis C virus genotype 2‐Infected japanese patients. Adv Ther. 2017; 34:1449–1465.
    1. Koletzki D, Dumont S, Vermeiren H, Fevery B, De Smet P, Stuyver LJ. Development and evaluation of an automated hepatitis C virus NS5B sequence‐based subtyping assay. Clin Chem Lab Med. 2010; 48:1095–1102.
    1. Murphy DG, Willems B, Deschenes M, Hilzenrat N, Mousseau R, Sabbah S. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5′ untranslated region sequences. J Clin Microbiol. 2007; 45:1102–1112.
    1. Katoh K, Asimenos G, Toh H. Multiple alignment of DNA sequences with MAFFT. Methods Mol Biol. 2009; 537:39–64.
    1. Saitou N, Nei M. The neighbor‐joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987; 4:406–425.
    1. Studier JA, Keppler KJ. A note on the neighbor‐joining algorithm of Saitou and Nei. Mol Biol Evol. 1988; 5:729–731.
    1. Hasegawa M, Kishino H, Yano T. Dating of the human‐ape splitting by a molecular clock of mitochondrial DNA. J Mol Evol. 1985; 22:160–174.
    1. Pilot‐Matias T, Tripathi R, Cohen D, et al. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT‐450. Antimicrob Agents Chemother. 2015; 59:988–997.
    1. Tripathi RL, Krishnan P, He Y, et al. Replication efficiency of chimeric replicon containing NS5A‐5B genes derived from HCV‐infected patient sera. Antiviral Res. 2007; 73:40–49.
    1. Schmitt M, Scrima N, Radujkovic D, et al. A comprehensive structure‐function comparison of hepatitis C virus strain JFH1 and J6 polymerases reveals a key residue stimulating replication in cell culture across genotypes. J Virol. 2011; 85:2565–2581.
    1. Mizokami M, Dvory‐Sobol H, Izumi N, et al. Resistance analyses of japanese hepatitis C‐Infected patients receiving sofosbuvir or ledipasvir/sofosbuvir containing regimens in phase 3 studies. J Viral Hepat. 2016; 23:780–788.
    1. Tripathi RL, Krishnan P, He Y, et al. Replication efficiency of chimeric replicon containing NS5A‐5B genes derived from HCV‐infected patient sera. Antiviral Res. 2007; 73:40–49.
    1. Ng TI, Krishnan P, Pilot‐Matias T, et al. In vitro antiviral activity and resistance profile of the next‐generation hepatitis c virus ns5a inhibitor pibrentasvir. Antimicrob Agents Chemother. 2017; 61 e02558–2616 [pii], 10.1128/AAC.02558‐16
    1. Schmitt M, Scrima N, Radujkovic D, et al. A comprehensive structure‐function comparison of hepatitis C virus strain JFH1 and J6 polymerases reveals a key residue stimulating replication in cell culture across genotypes. J Virol. 2011; 85:2565–2581.
    1. Mizokami M, Dvory‐Sobol H, Izumi N, et al. Resistance analyses of japanese hepatitis c‐infected patients receiving sofosbuvir or ledipasvir/sofosbuvir containing regimens in phase 3 studies. J Viral Hepat. 2016; 23:780–788.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する